⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Lecanemab

لکانماب

⚠ Unverified

🧠 Nervous SystemAnti-amyloid-beta antibody

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Safety not established 👴 Older adults:No specific problem stated 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA approved (BLA) BLA761269 ATC N06DX04

Market / country: 🇺🇸 USA

Leqembi (US)

🧮 Dose calculator

Disease / regimen

Alzheimer's disease · Regimen source: FDA Leqembi · 2.2, Table 1

• After 18 months: continue, or maintenance 10 mg/kg every 4 weeks. Subcutaneous: start 500 mg weekly, maintenance 360 mg weekly. Before starting: ApoE ε4 testing and baseline MRI; MRI at months 1, 2, 3 and 6. FDA Leqembi · 2.2 FDA Leqembi · 2.4 FDA Leqembi · Boxed Warning

Formulation

Age *

Weight (kg) *

Enter age and weight.

🛡️ Safety & information

Contraindications

⛔ Serious hypersensitivity to lecanemab (angioedema, anaphylaxis). FDA Leqembi · 4

Warnings

• Boxed warning: amyloid-related imaging abnormalities (ARIA-E/ARIA-H), sometimes fatal; intracerebral haemorrhage >1 cm; more frequent in ApoE ε4 homozygotes; caution with anticoagulants and thrombolytics. FDA Leqembi · Boxed Warning
• Infusion-related and hypersensitivity reactions. FDA Leqembi · 5

Formulations

100 mg/mL vial (500 mg/5 mL, 200 mg/2 mL) — injection 🇺🇸 USA FDA Leqembi · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Leqembi · 8.1
“Risk Summary There are no adequate data on LEQEMBI use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Leqembi · 8.2
“Risk Summary There are no data on the presence of lecanemab-irmb in human milk, the effects on the breastfed infant, or the effects of the drug on milk production.”
👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Leqembi · 8.4
“Safety and effectiveness of LEQEMBI in pediatric patients have not been established.”
👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Leqembi · 8.5
“No overall differences in safety or effectiveness of LEQEMBI have been observed between patients 65 years of age and older and younger adult patients.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)BLA761269
DailyMed (FDA label)FDA Leqembi
MedlinePlus (NIH)Lecanemab-irmb Injection
WHO ATC/DDDN06DX04
Darooyab (Iran)❌ None

🇮🇷 Not found in Iran list Darooyab · search

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Leqembi · 3 FDA Leqembi · 2.2, Table 1 FDA Leqembi · 2.2 FDA Leqembi · 2.4 FDA Leqembi · Boxed Warning FDA Leqembi · 4 FDA Leqembi · 5 FDA Leqembi · SPL approval / marketing category FDA Leqembi · 8.1 FDA Leqembi · 8.2 FDA Leqembi · 8.4 FDA Leqembi · 8.5
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · search
Clinical review⚠ Unverified

🔗 Similar drugs

For the same diseases

Brexpiprazole Donepezil Galantamine Memantine Rivastigmine